-
Latest MS Clinical Trial Data to be Presented at Congress of the European Academy of Neurology (EAN)
The latest clinical trial data from Genentech was presented at the 4th European Academy of Neurology (EAN) in June. They are expected to detail the results of a Phase 3 study, which indicates that treatment with Ocrevus (ocrelizumab) slows disability progression in primary progressive multiple sclerosis (PPMS) in ways that could delay the need for a wheelchair by up to seven years.
Read more here: #EAN2018 – Ocrevus May Delay Progression to Wheelchair by Up to 7 Years, New Analysis of PPMS Patient Data Shows
What do you think about this research news?
-
0 Replies
Sorry, there were no replies found.
Log in to reply.